Table III.
Antitumor activity and body weight changes in mice implanted with tumors from human breast cancer MX-1 cells or human non-small cell lung cancer NCI-H460 cells, following treatment with S-1 and the multi-kinase inhibitor, sunitinib.
| Body weight changed
|
|||||||
|---|---|---|---|---|---|---|---|
| Tumor | Drug (mg/kg) | Treatment | Tumor volumea (mm3, mean ± SD) | TGIb (%) | GDPc (days) | (g, mean ± SD) | (%) |
| MX-1 | Control | - | 2747±497 | - | 0.0 | 4.2±0.9 | 19.0 |
| S-1 (8.3) | days 1–14 | 1832±112 | 33.3 | 1.6 | 3.7±0.6 | 16.7 | |
| Sunitinib (20) | days 1–14 | 1231±222 | 55.2 | 3.1 | 3.4±1.1 | 15.2 | |
| S-1 + sunitinib | 811±148e | 70.5 | 5.4 | 2.4±1.0 NS | 10.4 | ||
| NCI-H460 | Control | - | 2937±709 | - | 0.0 | 2.6±1.3 | 10.0 |
| S-1 (8.3) | days 1–14 | 2206±279 | 24.9 | 1.5 | 1.3±1.8 | 4.9 | |
| Sunitinib (20) | days 1–14 | 1826±232 | 37.9 | 2.0 | 2.5±1.0 | 9.9 | |
| S-1 + sunitinib | 1282±120e | 56.4 | 3.0 | 1.5±0.7 NS | 5.8 | ||
a
Tumor volume on day 15;
b
tumor growth inhibition ratio on day 15;
c
GDP is the difference in time taken for the RTV to reach 5.0 between the treated and the control groups;
d
relative body weight change between days 0 and day 15;
e
overall maximal P<0.01 by closed testing procedure using the Aspin-Welch t-test; NS, overall maximal P>0.05 by closed testing procedure using the Aspin-Welch t-test; GDP, growth delay period; RTV, relative tumor growth; S-1, tegafur-gimeracil-oteracil.